<DOC>
	<DOCNO>NCT02943239</DOCNO>
	<brief_summary>Assess safety tolerability REGN2477 alone combine REGN1033 health postmenopausal woman .</brief_summary>
	<brief_title>Study Safety , Tolerability , Pharmacokinetics REGN2477 Alone Combination With REGN1033 Healthy Postmenopausal Women</brief_title>
	<detailed_description>Assess safety tolerability REGN2477 alone combine REGN1033 health postmenopausal woman . Effect REGN2477 alone , REGN1033 alone REGN2477+REGN1033 combination muscle body composition . Measure amount REGN2477 REGN1033 blood . Assess presence absence antibody REGN2477 REGN1033 .</detailed_description>
	<criteria>Postmenopausal woman age 45 70 year BMI 18 32 kg/m2 , inclusive Willing able maintain current diet , supplement physical activity level throughout study Provides sign informed consent Significant illness history significant illness Contraindication MRI History human immunodeficiency virus ( HIV ) ; hepatitis B hepatitis C virus ( HCV ) History immobilization , major surgical procedure , fracture , major trauma within 9 month prior screen History significant gynecological disorder malignancy ; history breast malignancy ( uterine fibroid dysfunctional uterine bleed acceptable ) Inconsistent vigorous physical activity ( few 5 day per week ) , intermittent weight lift History hypersensitivity reaction tetracycline antibiotic ( include doxycycline ) , vaccine , biologics Use agent alter muscle mass stable dose 3 month prior screen ( include protein supplement ) , use weight alter anabolic steroid drug ( include drug obesity , diuretic , testosterone ) Patients treat biologic therapy biologic immunotherapy previous 12 week prior screen study</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>